Tissue factor and tissue factor pathway inhibitor as key regulators of global hemostasis: Measurement of their levels in coagulation assays

Seminars in Thrombosis and Hemostasis

Volumn 36, Issue 7, 2010, Pages 764-771

  Kasthuri, Raj S ^a   Glover, Sam L ^a   Boles, Jeremiah ^a   MacKman, Nigel ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

thromboelastography; thrombosis; Tissue factor; tissue factor pathway inhibitor

Indexed keywords

BLOOD CLOTTING FACTOR 7A; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR;

BLEEDING; BLOOD CLOTTING; BLOOD CLOTTING TIME; HEMOSTASIS; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; REVIEW; THROMBIN TIME; THROMBOELASTOGRAPHY; THROMBOEMBOLISM; THROMBOSIS; VENOUS THROMBOEMBOLISM;

ANIMALS; BLOOD COAGULATION; BLOOD COAGULATION DISORDERS; HEMOSTASIS; HUMANS; LIPOPROTEINS; MICE; THROMBOPLASTIN; THROMBOSIS; VENOUS THROMBOEMBOLISM;

EID: 78049261563     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0030-1265293     Document Type: Review

References (32)

1. Gross P L., Weitz J I. New antithrombotic drugs. Clin Pharmacol Ther 2009 86 (2) 139-146
2. Howard E L., Becker K C., Rusconi C P., Becker R C. Factor IXa inhibitors as novel anticoagulants. Arterioscler Thromb Vasc Biol 2007 27 (4) 722-727
3. Mackman N, Taubman M. Tissue factor: past, present, and future. Arterioscler Thromb Vasc Biol 2009 29 (12) 1986-1988
4. Tilley R, Mackman N. Tissue factor in hemostasis and thrombosis. Semin Thromb Hemost 2006 32 (1) 5-10
5. Censarek P, Bobbe A, Grandoch M, Schrör K, Weber A A. Alternatively spliced human tissue factor (asHTF) is not pro-coagulant. Thromb Haemost 2007 97 (1) 11-14
6. Bach R R. Tissue factor encryption. Arterioscler Thromb Vasc Biol 2006 26 (3) 456-461
7. Maroney S A., Mast A E. Expression of tissue factor pathway inhibitor by endothelial cells and platelets. Transfus Apheresis Sci 2008 38 (1) 9-14
8. Hackeng T M., Rosing J. Protein S as cofactor for TFPI. Arterioscler Thromb Vasc Biol 2009 29 (12) 2015-2020
9. Heit J A. Cancer and venous thromboembolism: scope of the problem. Cancer Control 2005 12 (Suppl 1) 5-10
10. Kasthuri R S., Taubman M B., Mackman N. Role of tissue factor in cancer. J Clin Oncol 2009 27 (29) 4834-4838
11. Tesselaar M E., Romijn F P., Van Der Linden I K., Prins F A., Bertina R M., Osanto S. Microparticle-associated tissue factor activity: a link between cancer and thrombosis? J Thromb Haemost 2007 5 (3) 520-527
12. Khorana A A., Francis C W., Menzies K E. et al. Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer. J Thromb Haemost 2008 6 (11) 1983-1985
13. Dahm A, Van Hylckama Vlieg A, Bendz B, Rosendaal F, Bertina R M., Sandset P M. Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis. Blood 2003 101 (11) 4387-4392
14. Duering C, Kosch A, Langer C, Thedieck S, Nowak-Göttl U. Total tissue factor pathway inhibitor is an independent risk factor for symptomatic paediatric venous thromboembolism and stroke. Thromb Haemost 2004 92 (4) 707-712
15. Ariëns R A., Alberio G, Moia M, Mannucci P M. Low levels of heparin-releasable tissue factor pathway inhibitor in young patients with thrombosis. Thromb Haemost 1999 81 (2) 203-207
16. Bladbjerg E M., Madsen J S., Kristensen S R. et al. Effect of long-term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study. J Thromb Haemost 2003 1 (6) 1208-1214
17. Amini-Nekoo A, Futers T S., Moia M, Mannucci P M., Grant P J., Ariëns R A. Analysis of the tissue factor pathway inhibitor gene and antigen levels in relation to venous thrombosis. Br J Haematol 2001 113 (2) 537-543
18. Sidelmann J J., Bladbjerg E M., Gram J, Münster A M., Jespersen J. Tissue factor pathway inhibitor relates to fibrin degradation in patients with acute deep venous thrombosis. Blood Coagul Fibrinolysis 2008 19 (5) 405-409
19. Hoke M, Kyrle P A., Minar E et al. Tissue factor pathway inhibitor and the risk of recurrent venous thromboembolism. Thromb Haemost 2005 94 (4) 787-790
20. Ollivier V, Wang J, Manly D et al. Detection of endogenous tissue factor levels in plasma using the calibrated automated thrombogram assay. Thromb Res 2010 125 (1) 90-96
21. Haubold K, Rink M, Spath B et al. Tissue factor procoagulant activity of plasma microparticles is increased in patients with early-stage prostate cancer. Thromb Haemost 2009 101 (6) 1147-1155
22. Santucci R A., Erlich J, Labriola J et al. Measurement of tissue factor activity in whole blood. Thromb Haemost 2000 83 (3) 445-454
23. Marsik C, Quehenberger P, Mackman N, Osterud B, Luther T, Jilma B. Validation of a novel tissue factor assay in experimental human endotoxemia. Thromb Res 2003 111 (45) 311-315
24. Zillmann A, Luther T, Müller I et al. Platelet-associated tissue factor contributes to the collagen-triggered activation of blood coagulation. Biochem Biophys Res Commun 2001 281 (2) 603-609
25. Koch L, Hofer S, Weigand M A., Frommhold D, Poeschl J. Lipopolysaccharide-induced activation of coagulation in neonatal cord and adult blood monitored by thrombelastography. Thromb Res 2009 124 (4) 463-467
26. Parhami-Seren B, Butenas S, Krudysz-Amblo J, Mann K G. Immunologic quantitation of tissue factors. J Thromb Haemost 2006 4 (8) 1747-1755
27. Luther T, Flössel C, Hietschhold V, Koslowski R, Müller M. Flow cytometric analysis of tissue factor (TF) expression on stimulated monocytescomparison to procoagulant activity of mononuclear blood cells. Blut 1990 61 (6) 375-378
28. Shet A S., Aras O, Gupta K et al. Sickle blood contains tissue factor-positive microparticles derived from endothelial cells and monocytes. Blood 2003 102 (7) 2678-2683
29. Zwicker J I., Liebman H A., Neuberg D et al. Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. Clin Cancer Res 2009 15 (22) 6830-6840
30. Bogdanov V Y., Cimmino G, Tardos J G., Tunstead J R., Badimon J J. Assessment of plasma tissue factor activity in patients presenting with coronary artery disease: limitations of a commercial assay. J Thromb Haemost 2009 7 (5) 894-897
31. Key N S., Slungaard A, Dandelet L et al. Whole blood tissue factor procoagulant activity is elevated in patients with sickle cell disease. Blood 1998 91 (11) 4216-4223
32. Aras O, Shet A, Bach R R. et al. Induction of microparticle- and cell-associated intravascular tissue factor in human endotoxemia. Blood 2004 103 (12) 4545-4553